Biotech M&A hits $106 billion, on track for best year since pre-Covid
Global biopharma M&A is experiencing a sharp uptick, putting the sector on track for its strongest year since the pre-pandemic peak seven years ago. Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma’s race to beef up their pipelines, dealmaking so far in 2026 amounted to $106 billion over 201 deals, according...
